A nationwide, register-based cohort study in Finland included 61,889 hospitalized patients with schizoaffective and schizophrenia spectrum disorders (SSD), focusing on relapse defined as inpatient hospital care for psychosis...
Maintenance Electroconvulsive Therapy Proves Effective for Treatment-Resistant Schizophrenia
A recent study aimed to evaluate the efficacy and safety of maintenance electroconvulsive therapy (M-ECT) in patients with treatment-resistant schizophrenia...
Josh Hamilton,
DNP, APRN-BC, CTMH, CNE, CLNC, FAANP
Chief Clinical Officer, The Hamilton Group Behavioral Health LLC
FDA Accepts New Drug Application for Xanomeline-Trospium
Karuna Therapeutics announced that the FDA accepted their New Drug Application for KarXT (xanomeline-trospium), a treatment for schizophrenia in adults...
Michael Asbach,
DMSc, PA-C, Psych-CAQ
Associate Director, Interventional Psychiatry, DENT Neurologic Institute
Even though data support long-acting injectable (LAI) efficacy, safety, and improved adherence over oral formulations, there are numerous misconceptions about...
Josh Hamilton,
DNP, APRN-BC, CTMH, CNE, CLNC, FAANP
Chief Clinical Officer, The Hamilton Group Behavioral Health LLC
Targeting Cognitive Impairment in Schizophrenia: Treatment
Cognitive impairment is a significant characteristic of schizophrenia, contributing to poor functional outcomes. At the neurochemical level, N-methyl-d-aspartate receptor (NMDAR)...
Josh Hamilton,
DNP, APRN-BC, CTMH, CNE, CLNC, FAANP
Chief Clinical Officer, The Hamilton Group Behavioral Health LLC
Addressing the Underutilization of LAIs in a Community Health Setting
The use of long-acting injectable (LAI) antipsychotic medication is considered a recommended treatment for patients who have difficulty taking daily...
Josh Hamilton,
DNP, APRN-BC, CTMH, CNE, CLNC, FAANP
Chief Clinical Officer, The Hamilton Group Behavioral Health LLC
